Breaks Categories: Stock Spotlights

TuesdayJan 17, 2017 9:17 am

NetworkNewsBreaks – Amyris, Inc. (NASDAQ: AMRS) Making Technological Breakthroughs under Guidance of Highly Experienced Management

Amyris (NASDAQ: AMRS) is one of the fastest growing industrial biotechnology companies among the 2,772 in the U.S today. The company's eight-person management team is comprised of hand-picked individuals with a proven ability to innovate and build companies in a number of industries. With over 30 years of experience as a tech entrepreneur and thought leader, president and CEO John Melo has led Amyris from technology development and industrial startup to product development and final commercialization. Thanks to the team's level of experience, Amyris has made outstanding technological breakthroughs, among these is the world's leading treatment for malaria, saving over…

Continue Reading

FridayJan 13, 2017 2:09 pm

NetworkNewsBreaks – Medical Transcription Billing, Corp. (NASDAQ: MTBC) Embraces Possible Obamacare Changes in Trump Presidency

Medical Transcription Billing (NASDAQ: MTBC) (NASDAQ: MTBCP) offers services that could actually become more sought-after following changes to health insurance laws. “There are concerns that if the Trump administration completely repeals Obamacare, this might remove the need for a series of services currently offered by healthcare technology companies, such as revenue cycle management or more comprehensive practice management solutions.” … “Medical Transcription Billing believes the exact opposite. The company’s management feels that it is very unlikely that the Trump administration and the Republican-led Congress will completely eliminate insurance for 25 million Americans. The more likely scenario is that the administration…

Continue Reading

FridayJan 13, 2017 2:03 pm

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Remains Steady in Position as O2O Service Leader; Anticipates Revenue Boost with Xinhua Game Channel

Moxian, Inc. (NASDAQ: MOXC) continues to position itself as a leader in the O2O service market and a competitive digital marketing company in China by presenting new platforms. “Launched as a joint effort with Xinhua New Media and aimed at further strengthening the company’s partnership with Xinhua New Media Culture Communication Co., Ltd., the game channel is expected to bring multiple benefits to the company, including higher revenue streams from advertisement sales and game downloads, as well as ultimately attracting new users for its own Moxian+ platform and app. The project can bring massive exposure to the company’s services, given…

Continue Reading

FridayJan 13, 2017 1:58 pm

NetworkNewsBreaks – Naked Brand Group, Inc. (NASDAQ: NAKD) Shares Skyrocket on LOI to Merge with Bendon Limited

Shares of Naked Brand Group (NASDAQ: NAKD) soared 173% following this morning’s announcement that the company has entered into a letter of intent for a proposed merger with Bendon Limited to create a portfolio of innerwear, sleepwear and swimwear brands. Per the agreement, Bendon gains immediate access to the U.S. market while Naked will be able to leverage Bendon’s well-established global distribution channels. Naked CEO Carol Hochman will serve as COO of the emerging company. “We are extremely excited about the potential of this proposed merger, and look forward to capitalizing on Bendon’s scale and expertise to further expand the…

Continue Reading

ThursdayJan 12, 2017 2:16 pm

NetworkNewsBreaks – Transgenomic, Inc. (NASDAQ: TBIO) Shares Skyrocket on Licensing Deal with LifeLabs for ICE COLD-PCR, Canadian Patent Allowance

Shares of Transgenomic (NASDAQ: TBIO) are up roughly 169% late morning on word of its licensing agreement with Canadian laboratory service provider LifeLabs, which will use Transgenomics’ ICE COLD-PCR (ICP) technology as its mutation enrichment platform for cancer testing. The three-year renewable agreement permits LifeLabs to benefit from technology improvements and additional product launches during its term. Separately, Transgenomic also announced issuance of a new Canadian patent for ICP which covers the use of the ICE COLD-PCR method that enriches mutated DNA sequences in a background of normal DNA through to 2030. “We believe that this sizable commercial licensing agreement…

Continue Reading

ThursdayJan 12, 2017 2:13 pm

NetworkNewsBreaks – BioLargo, Inc. (BLGO) on Cusp of Commercial Betas of AOS Filter System

BioLargo (OTCQB: BLGO) is a science and technology company that, for the last decade, has continued to innovate sustainable, disruptive technology-based science products designed to help solve problems threatening the world’s supply of water, food, agriculture, health care and energy. As an “invention” company, BioLargo and its subsidiaries deliver impactful products and services featuring BioLargo® Technology for both regulated and unregulated uses and applications. Last fall, the company announced the completion of the alpha unit of its advanced water treatment system - the AOS Filter (advanced oxidation system) – for applications ranging from food and agriculture to ballast water treatment.…

Continue Reading

WednesdayJan 11, 2017 3:33 pm

NetworkNewsBreaks – Guitammer (GTMM) Reports 475% Increase in FY2016 ButtKicker® Sales; Says 2017 Will Be Even Better

Reporting a triple-digit sales increase of its ButtKicker®-equipped cinema seats for full-year 2016, The Guitammer Company (OTCQB: GTMM) forecasts that its performance in 2017 will be even stronger. The Ohio-based company yesterday said it sold over 11,300 new ButtKicker®-equipped cinema seats for 57 new auditoriums in 2016, marking a 475% increase compared to 12 auditoriums and over 2,500 seats in 2015. There are now more than 20,000 ButtKicker-enabled seats in over 105 cinema auditoriums worldwide. The company also guided for continued growth this year, and said it expects to ship ButtKicker products for 1,000 seats in five new auditoriums by…

Continue Reading

WednesdayJan 11, 2017 3:26 pm

NetworkNewsBreaks – Petrogas (PTCO) Shares Climb on Acquisition of Fractional Interest in Texas

Shares of Petrogas Company (OTC: PTCO) are up 9% after the company said it has acquired a fractional interest in 11 oil and gas wells operated by Vanguard Operating (NASDAQ: VNR) in Cherokee County, Texas. Only some of the wells are currently producing hydrocarbons. "This is the type of acquisition we love to make as most of these wells had their production turned off in 2014 when oil prices began sliding. Now that prices are coming back to profitable levels, we expect that all offline wells could be brought back to production with minimal effort over the coming months," Petrogas…

Continue Reading

WednesdayJan 11, 2017 2:38 pm

NetworkNewsBreaks – Ironclad Performance Wear (ICPW) Strategizes to Buck Impact of Oil & Gas Uncertainties

Ironclad Performance Wear (OTCQB: ICPW) designs and manufactures work wear for various construction, do-it-yourself, industrial, sporting goods, and general services markets – a focus that generated third quarter 2016 sales of $6.45 million, up 19.1% year-over-year. The company specializes in task-specific gloves, such as the KONG® original, which was co-developed by the oil and gas industry safety committee for use in oil and gas drilling, extraction and refining, fracking, and many other construction-related fields. On the same note, Ironclad is hedging itself against struggles of the current oil and gas market, focusing on expansion in other key segments. To learn…

Continue Reading

WednesdayJan 11, 2017 2:30 pm

NetworkNewsBreaks – Sangamo Therapeutics, Inc. (NASDAQ: SGMO): FDA Grants Orphan Drug Designation for SB-318

Sangamo Therapeutics (NASDAQ: SGMO) is trading higher this morning on news the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s SB-318, a genome editing product candidate for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare lysosomal storage disorder. The FDA grants orphan drug designation to drugs and biologics intended to treat rare diseases, providing incentives to advance development of rare disease drugs as well as commercialization of drugs that progress to approval. Sangamo also noted its plans to “conduct the first ever in vivo genome editing clinical trials including Phase 1/2 studies…

Continue Reading